Pharma Times
DECEMBER 22, 2021
Calls for booster vaccinations in order to combat the rising cases brought about by winter and the recent Omicron variant have intensified, in the midst of record case rates.
pharmaphorum
DECEMBER 21, 2021
Sanofi has bolstered its immuno-oncology pipeline with a $1 billion agreement to acquire Amunix Pharma of the US – its fourth bolt-on deal of 2021. South San Francisco-based Amunix specialises in T-cell engager and cytokine-based treatments for solid tumours, and is planning to advance its lead programme AMX-818 – a cell-based therapy which targets HER2-expressing cancers – into the clinic next year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
DECEMBER 21, 2021
The organization is working to give oncology professionals the chance to hear directly from patients about their unique experiences, concerns, and hopes.
Drug Patent Watch
DECEMBER 22, 2021
Annual Drug Patent Expirations for CORLANOR Corlanor is a drug marketed by Amgen Inc and is included in two NDAs. It is available from one supplier. There are eight patents…. The post New patent for Amgen Inc drug CORLANOR appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
DECEMBER 21, 2021
The DETERMINE trial aims to discover whether existing ‘licensed’ drugs could also benefit patients with rare cancer types that the drug is not currently licensed for.
pharmaphorum
DECEMBER 22, 2021
A group of 15 digital health startups have joined a programme set up by the US federal government to address health inequality and mitigate the effects if the COVID-19 pandemic. The PandemicX accelerator, launched by the Department of Health and Human Services, is focused on “using digital tools and publicly accessible data to eliminate disparities and tackle drivers of inequity exacerbated by COVID-19.” Companies that have been invited to take part will get “curriculum, mentor
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Marketing Network
DECEMBER 20, 2021
R.J. Lewis, Founder and CEO of eHealthcare Solutions and Tap Native and the Chief Collaborator at Pharma Marketing Network, moderated a deep dive discussion on the topic of physician-level data (PLD) with a focus around drivers for the tool, its usage, and successes learnings about its function in pharma, and the where it’s heading. Guests of the panel included experts from GSK, Ispen, BioPharm Communications, and CMI, who all spoke to the importance of incorporating and leveraging PLD ins
Pharma Times
DECEMBER 22, 2021
With authorisation, Pfizer’s oral antiviral candidate Paxlovid is an investigational SARS-CoV-2 protease inhibitor could be prescribed at the first sign of COVID-19 infection.
pharmaphorum
DECEMBER 24, 2021
Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up to recently approved Aduhelm. The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease.
Outsourcing Pharma
DECEMBER 20, 2021
According to an expert from the clinical insights company, prejudice in AI can impact patient outcomes as well as the ability to develop effective treatments.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
DECEMBER 22, 2021
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
DECEMBER 20, 2021
It is estimated that chronic kidney disease affects more than 160 million people with type 2 diabetes worldwide.
pharmaphorum
DECEMBER 21, 2021
In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that took years (if not decades). Yet a successful COVID-19 vaccine gained emergency approval in just 11 months, a blistering pace that likely saved millions of lives. Such a fast turnaround would not have been possible without advanced analytics and the troves of intelligence that scientists had at their disposal.
NY Times
DECEMBER 23, 2021
The F.D.A. said the drug should be prescribed mainly when other treatments were “not accessible or clinically appropriate.”.
Drug Channels
DECEMBER 19, 2021
Happy New Year, everyone! We made it through a challenging 2021. Ring in 2022 with these noisemakers from the Drug Channels party bag: Hospitals earn incredible markups on CAR-T therapies Utilization management booms Health plans often ignore clinical guidelines Benefit designs flummox physicians Plus: an awesomely concise summary of U.S. health insurance.
Pharma Times
DECEMBER 21, 2021
With approval, Saphnelo would be the first available treatment for systematic lupus erythematosus in Europe in over ten years.
pharmaphorum
DECEMBER 23, 2021
The FDA has published draft guidance on how digital health technologies (DHTs) like smart and wearable devices can be used to capture data remotely from patients in clinical trials – an approach that has come to the fore since the start of the pandemic. The new guidance sets out the regulator’s current thinking on how trial sponsors to incorporate DHTs in the design of studies of drugs or medical devices.
Outsourcing Pharma
DECEMBER 22, 2021
OSPâs list of the yearâs most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
NY Times
DECEMBER 22, 2021
The first-of-its-kind treatment, Paxlovid, has been found to be highly protective against severe illness. It could be available within a few days.
Pharma Times
DECEMBER 23, 2021
Government vaccine advisers have said vulnerable primary school children should be offered a low-dose of a COVID-19 vaccine.
pharmaphorum
DECEMBER 22, 2021
Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action. However, we have seen a framework of guidelines and recommendations during the last year on everything from increasing diversity to producing lay summaries, start to take shape. As part of our 2021 in Review series, we look back over some of these developments.
Pharma in Brief
DECEMBER 23, 2021
Changes to the Patented Medicine Prices Review Board ( PMPRB ) regime, contained in pending amendments to the Patented Medicines Regulations , have been delayed until July 1, 2022. These amendments form the basis for new PMPRB Guidelines. The PMPRB has updated its website to indicate that the new Guidelines will be in place as of the coming-into-force of the amendments.
NY Times
DECEMBER 22, 2021
The caps come as the rapid spread of the Omicron variant has customers flocking to testing sites and pharmacies, which are struggling to keep up.
Pharma Times
DECEMBER 20, 2021
Tetris Pharma’s Ogluo is the first ready-to-use, pre-mixed and pre-measured glucagon injection.
pharmaphorum
DECEMBER 24, 2021
The World Health Organization (WHO) recently held a virtual panel discussion during Digital Health Week with speakers from around the world to talk about global strategy on digital health and collective opportunities for catalysing collaborative action. The panel focused on the objectives of the WHO’s Global Strategy on Digital Health 2020-2025 , which aims to develop partnerships at national, regional and global levels to align resources and investments to focus on sustainability and grow
Pharma Mirror
DECEMBER 24, 2021
Getting bariatric surgery is a lifesaver for many people. It can dramatically improve the quality of life of those that are having problems because of their obesity. It reduces and even eliminates diabetes in many people and seriously reduces the risk of heart disease. The weight loss can be dramatic as well. Starting almost immediately after the surgery, the pounds fall away with ease.
NY Times
DECEMBER 21, 2021
About 150,000 babies are born each year in Nigeria with sickle cell, a deadly disease. Tens of thousands of them die annually before their fifth birthdays.
Pharma Times
DECEMBER 23, 2021
WHO officials remain cautious about claiming Omicron as a milder variant of the COVID-19 virus.
pharmaphorum
DECEMBER 23, 2021
At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year. The FDA has approved the drug under the Leqvio trade name as an adjunct to maximum-dose statin drugs for people who need further LDL-cholesterol reduction to reach targets, a year after it was given a green light in Europe.
Pharma Packaging Solutions
DECEMBER 24, 2021
So he came and proclaimed peace to you who were far off and peace to those who were near, for through him both of us have access in one Spirit to the Father. So then you are no longer strangers and aliens, but you are citizens with the saints and also members of the household of God. Ephesians 2:17-19 NRSV God’s purpose and longing for his creation has always been that we might not only be recipients of his great love and peace, but that we might be his partners in bringing that love and peace t
NY Times
DECEMBER 20, 2021
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for the treatment.
Drug Patent Watch
DECEMBER 23, 2021
Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are two…. The post New patent expiration for Pacira Pharms drug EXPAREL appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
DECEMBER 22, 2021
Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect. Just a few weeks France’s Sanofi made a $40 million investment in Gyroscope for first refusal rights on the gene therapy – called GT005 – but it is Novartis that has swooped on the company and its main asset.
Pharma Packaging Solutions
DECEMBER 22, 2021
He has shown you, o mortal, what is good, and what does the Lord require of you? To do justice, to love Mercy, and to walk humbly before God. Micah 6:8 NRSV Requirements are placed on all of us from time to time. As a child, my family had morning prayer time at 4:00 a.m. At that time a bell was rung three times. Although I slept very near the living room, I didn’t always hear the bell immediately.
PharmD Live
DECEMBER 21, 2021
1. Fee-for-service reimbursement falls as quality performance pay increases. A 3.75% cut in the 2022 Medicare conversion factor, which calculates reimbursement for procedures under fee-for-service, is mandated under a budget neutrality provision and comes after a pay bump from Congress that expires in 2022. Meanwhile, quality performance pay is increasing.
Expert insights. Personalized for you.
121 
Let's personalize your content